Neurodegenerative conditions, including Alzheimer's and Parkinson's disease, progressively impair neurons, resulting in the deterioration of motor functions, memory, and cognitive abilities, profoundly affecting individuals and the healthcare system. Existing therapies provide temporary symptom management and do not stop the advancement of the diseases. The challenge of researching these conditions is compounded by the blood-brain barrier, which limits drug delivery, and by inadequate disease models. Post-mortem tissue cultures, immortalized cell lines, and animal models do not effectively replicate human disease pathology.
Advanced cell models like iPSCs and 3D cultures offer potential solutions to these research obstacles. iPSCs enable the creation of patient-specific disease models and the screening of therapeutic compounds, whereas 3D cultures mimic the architecture of the brain, allowing for more intricate disease investigation and the expansion of drug testing capabilities. Additionally, these models alleviate ethical issues associated with the use of embryonic stem cells.
Along with the promise of iPSCs in disease modeling comes many challenges, including the need for standardized protocols and confirmation of their clinical applicability. To gain insights into the optimal use of iPSCs in disease modeling, download our eBook. It covers best practices for utilizing iPSCs, advice for efficient workflow management, and highlights cutting-edge solutions that enhance R&D for advanced cell models.
Download this eBook to learn:
- Solutions for culturing, maintaining and characterizing iPSCs
- The current standing of research on neurodegenerative disorders
- Progress made on neurodegenerative disorders using iPSCs and 3D cultures
- A study of motor neurons and microglia from healthy and ALS patients
- Comprehensive solutions for identifying neuronal characteristics and monitoring their development